Market Trends– category –
-
MSD-Moderna Personalized mRNA Neoantigen Combination Adjuvant Therapy Reports Positive Phase III Results in Melanoma
European Pharmaceutical Review USA Overview MSD (Merck) and Moderna's personalized mRNA neoantigen combination adjuvant therapy has announced positive results from its Phase III clinical trial in high-risk melanoma patients. The data sug... -
Global Summits Confront Cell & Gene Therapy Scale-Up: Automation, Cost Efficiency, and Mass Production Strategies
Informa Connect International Overview Upcoming international conferences, including Advanced Therapies Europe and the CAR-TCR Summit in September 2026, are set to address the urgent need for scalable and cost-effective manufacturing in ... -
Exosome-Based Therapeutics Development Summit Convenes in Boston to Address Manufacturing, Regulatory, and Clinical Challenges
Hanson Wade Conferences USA Overview The 8th Exosome-Based Therapeutics Development Summit will be held in Boston from September 22-24, 2026, focusing on overcoming challenges in scalable manufacturing, robust analytical characterization... -
6th iPSC Drug Development Summit Focuses on Manufacturability, Regulatory Alignment, and Scalable Development Models
RegMedNet UK Overview The 6th iPSC Drug Development Summit is being held to actively discuss the clinical and commercial feasibility of iPSC therapies. The summit will focus on manufacturability, alignment with regulatory authorities, an... -
Chinese Trial Reports 90% Heart Function Improvement in Phase 2 Heart Failure Patients Treated with iPSC-Derived Cardiomyocytes
South China Morning Post (SCMP) China Overview A Phase 2 clinical trial conducted by Nanjing Drum Tower Hospital in China, using iPSC-derived cardiomyocytes for heart failure treatment, demonstrated significant improvement in heart funct... -
Commercial-Scale iPSC Cell Therapy Production Gains Traction with US Clinical Trial Progress and Master Cell Bank Establishment
The Medicine Maker UK Overview Manufacturing challenges for commercial-scale iPSC cell therapies are being overcome, with multiple iPSC clinical trials progressing in the U.S. for indications like Type 1 Diabetes, Parkinson's disease, an... -
AI, Fintech, Biotech Lead 2026 Startup M&A: Anthropic Acquires Coefficient Bio for $400M, Expanding into Life Sciences
Value Add Pulse (via Crunchbase News data) USA Overview The 2026 startup M&A market saw significant activity across AI, Fintech, and Biotechnology sectors. A standout deal was frontier AI lab Anthropic's $400 million acquisition of b... -
Industrial AI Activity Jumps Over 218% in 2025, Generative AI and Physical AI Drive Manufacturing Commercialization
ABI Research Global Overview ABI Research reports that industrial AI activity surged by over 218% in 2025, driven by the expanding roles of generative AI, physical AI, and strategic partnerships in manufacturing. This rapid growth signif... -
AI Infrastructure Investment to Exceed $1.3 Trillion by 2027; H1 2026 Sees Record $430 Billion VC Inflow
S&P Global Ratings Global Overview Hyperscaler AI infrastructure investments are projected to surpass $1.3 trillion by 2027, according to S&P Global Ratings, with global AI venture capital hitting a record $430 billion in H1 2026—a 6... -
Broadcom Reportedly Negotiating Over $60 Billion Debt Financing for AI Chip Deals, Including Anthropic
Seeking Alpha USA Overview Broadcom is reportedly in talks with lenders, including Blackstone and Apollo Global Management, to raise over $60 billion in debt financing. This capital infusion is intended to fund AI chip deals for major AI...
